Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mayo Clinic

Sites in Rochester, MN

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 5:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1819
Shown on this page
12
Current sort
Recently updated
Campus scope
Mayo Clinic, Rochester, MN
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mayo Clinic, Rochester, MN. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 553–564 of 1,819 matching trials with a site at Mayo Clinic, Rochester, MN.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Not yet recruiting Not applicable Interventional

Dorsal Root Ganglion Stimulation After Lower Motor Neuron Damage

NCT07619300
Site status not listed — check the official record
View directory record Official record
Conditions
Spinal Cord Injuries, Lower Motor Neuron Disease
Interventions
Abbot Dorsal Root Ganglion Neurostimulator
Device
Lead sponsor
Peter J. Grahn, Ph.D.
Other
Eligibility
18 Years to 70 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Not yet recruiting Not applicable Interventional

Upper Extremity Vascularized Composite Allotransplantation: A Study Evaluating Safety, Functional Outcomes, and Patient-Reported Psychosocial Outcomes

NCT07810790
Site status not listed — check the official record
View directory record Official record
Conditions
Functional Recovery, Upper Extremity Vascularized Composite Allotransplantation
Interventions
Upper Extremity Vascularized Composite Allotransplantation (VCA)
Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2037
U.S. locations
9
States / cities
Los Angeles, California • New Haven, Connecticut • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Exercise-stimulated Muscle Glucose Uptake in Upper Body Obesity

NCT04532814
Site status not listed — check the official record
View directory record Official record
Conditions
Upper Body Obesity
Interventions
Exercise
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Active, not recruiting Not applicable Interventional

DSC-MRI in Measuring rCBV for Early Response to Bevacizumab in Patients With Recurrent Glioblastoma

NCT03115333
Site status not listed — check the official record
View directory record Official record
Conditions
Gliosarcoma, Recurrent Glioblastoma
Interventions
Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging
Diagnostic Test
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
58
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Castro Valley, California + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Active, not recruiting Phase 2 Interventional

Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia

NCT01841723
Site status not listed — check the official record
View directory record Official record
Conditions
Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia Variant
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Ibrutinib, Ultrasound Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2029
U.S. locations
5
States / cities
Bethesda, Maryland • Detroit, Michigan • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Preventive Human Papillomavirus (HPV) Vaccine Trial in Kidney Transplant Recipients

NCT03036930
Site status not listed — check the official record
View directory record Official record
Conditions
Human Papillomavirus Infection, Human Papillomavirus-Related Carcinoma
Interventions
Biospecimen Collection, HPV Self-Collection, Questionnaire Administration, Recombinant Human Papillomavirus Nonavalent Vaccine
Procedure · Other · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 49 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Active, not recruiting Phase 3 Interventional

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

NCT03533582
Site status not listed — check the official record
View directory record Official record
Conditions
Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma, Hepatoblastoma, Hepatocellular Malignant Neoplasm, Not Otherwise Specified
Interventions
Biospecimen Collection, Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Patient Observation, Resection, Sorafenib, Vincristine Sulfate
Procedure · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 30 Years
Enrollment
537 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
180
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 134 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Recruiting Phase 1Phase 2 Interventional

Safety of HRX215 in Patients After Minor and Major Liver Resection

NCT06638502
Status at this site: Recruiting
View directory record Official record
Conditions
Liver Resection, Colorectal Carcinoma Liver Metastases
Interventions
HRX215 capsules, Placebo capsules
Drug
Lead sponsor
HepaRegeniX GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Baltimore, Maryland • Rochester, Minnesota • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Recruiting No phase listed Observational

Biomarkers of Resiliency In Childhood Cancer Surgery

NCT06674811
Status at this site: Recruiting
View directory record Official record
Conditions
Pediatric Cancer, Neuroblastoma, Sarcoma, Wilms Tumor and Other Childhood Kidney Tumors, Childhood Soft Tissue Sarcoma, Childhood Bone Sarcoma, Childhood Malignant Intestinal Neoplasm, Childhood Malignant Liver Neoplasm, Childhood Malignant Lung Neoplasm, Childhood Malignant Ovarian Neoplasm, Childhood Malignant Pleural Neoplasm, Childhood Neuroblastic Tumor, Childhood Sarcoma
Interventions
Wearing Smartwatch, Patient Report Outcomes, Blood Draw, Clinical Data Review
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Years to 25 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Active, not recruiting Phase 3 Interventional

Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

NCT03267433
Site status not listed — check the official record
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Computed Tomography, Positron Emission Tomography, Rituximab, Rituximab and Hyaluronidase Human
Procedure · Biological
Lead sponsor
ECOG-ACRIN Cancer Research Group
Network
Eligibility
18 Years to 70 Years
Enrollment
689 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
374
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 236 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)

NCT06192875
Status at this site: Recruiting
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Non-Interventional Study
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2035
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:56 AM EDT
Recruiting Not applicable Interventional

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial

NCT04097145
Status at this site: Recruiting
View directory record Official record
Conditions
Tricuspid Regurgitation, Tricuspid Valve Insufficiency, Tricuspid Valve Disease
Interventions
Edwards PASCAL System, Optimal Medical Therapy
Device · Drug
Lead sponsor
Edwards Lifesciences
Industry
Eligibility
18 Years and older
Enrollment
1,270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2031
U.S. locations
73
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 59 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 23, 2026, 5:56 AM EDT

About this Mayo Clinic institution page

What this page lists
ClinicalTrials.gov records that list Mayo Clinic in Rochester, MN as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Mayo Clinic at any site, browse by condition, or browse by U.S. city.